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bstract
Familial hypercholesterolaemia (FH) is usually caused by mutations in the low density lipoprotein (LDL) receptor gene (LDLR) that impair
learance of LDL from the circulation. The increased risk of premature coronary heart disease associated with FH can be reduced by dietary
dvice and treatment with lipid-lowering drug therapy, but it is important to identify affected individuals at an early stage. Several programmes
or genetic diagnosis of FH that rely on identifying nucleotide substitutions in genomic DNA have been initiated, but the validity of these is
ependent on distinguishing between a silent nucleotide variant and a mutation that affects LDL-receptor function. Here we describe a single
ucleotide substitution in the coding region of exon 9 of LDLR that is an apparently silent polymorphism: CGG (Arg406) to AGG (Arg).
nalysis of mRNA from the patient’s cells showed that the mutation introduces a new splice site that is used to the exclusion of the natural
plice site and causes a deletion of 31 bp from the mRNA, predicted to introduce premature termination four codons after R406. This finding
mphasizes the caution needed in genetic diagnosis of FH based on genomic DNA sequence alone.
2007 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Familial hypercholesterolaemia (FH) is caused by defec-
ive clearance of low density lipoproteins (LDL) from the
irculation, leading to increased levels of serum LDL and
arkedly increased risk of atherosclerosis and premature
oronary heart disease [1]. FH is classically caused by dom-
nant loss-of-function mutations in the gene for the LDL
eceptor, and occurs with a frequency of about 1/400–500
n most populations, making heterozygous FH one of the
ommonest inherited single gene disorders. Homozygous FH
s very rare, and presents with a much more severe pheno-
ype [1]. One widespread and two very rare heterozygous
utations in the gene for apolipoprotein B, the major protein
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f LDL that is the ligand recognized by the LDL recep-
or, cause essentially the same phenotype as heterozygous
H, although the disorder is generally referred to as familial
efective apolipoprotein B (FDB) [2].
More recently, defects in other genes have been identified
hat impair the normal function of the LDL receptor pathway,
or example recessive loss-of-function mutations in ARH [3]
nd dominant gain-of-function mutations in PCSK9 [4], but
hese remain relatively rare causes of inherited hypercholes-
erolaemia. In contrast, loss-of-function mutations in PCSK9
re associated with a 40% reduction in serum cholesterol and
ighly significant protection from coronary heart disease [5].
his finding has emphasized that avoiding coronary heart dis-
ase depends on maintaining a low plasma cholesterol level
rom early in life [6].
The risk of coronary disease in FH can be significantly
educed by cholesterol-lowering therapy with statins, and the
vailability of these drugs has markedly improved prognosis
or FH patient [7]. However, it is important to commence pre-
entative advice and treatment at a young age and this can be
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ided by identification of the underlying genetic defect, which
llows unambiguous identification of affected relatives.
ndeed, the relative ease with which variants in genes can
ow be detected by high throughput sequencing of amplified
enomic DNA has allowed identification of numerous differ-
nt mutations in the LDL-receptor gene in FH patients [8–10].
learly if this information is to be used for diagnostic pur-
oses it is of the utmost importance that the effect of a poten-
ial mutation on LDL receptor function is known [11], but
his has not always been ascertained and some “mutations”
ave been reported that do not cause hypercholesterolaemia.
qually well, the effect of rare apparently silent mutations
hould be investigated. We demonstrate this here by report-
ng a mutation in exon 9 of the LDL-receptor gene that is not
redicted to cause an amino acid substitution, but does intro-
uce a new splice site. This results in deletion of 31 bp from
xon 9, predicted to introduce a premature termination codon
nd to result in a truncated protein with no residual function.
. Materials and methods
All the methods for sequencing LDL-receptor mRNA
rom EBV-transformed lymphocytes and genomic DNA from
hole blood have been published previously [12]. PCR
roducts were cloned into T-vector for sequencing with the
p6 or T7 primers according to the supplier’s instructions
Promega).. Results and discussion
The index patient attended the Hammersmith Hospital
ipid Clinic and had a diagnosis of probable heterozygous FH
m
e
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ig. 1. Potential splice cryptic site in exon 9 of the LDL receptor gene of an FH pat
s boxes and introns by lines, with the nucleotide substitution in codon 406 foun
ntron:exon junction between exons 8 and 9 is shown, and that surrounding the b
nd the new potential splice sites were calculated according to Zhang (http://rulai
hapiro and co-workers [18]. (B) Use of the new splice site is predicted to result insis 195 (2007) e17–e20
7], based on an untreated plasma cholesterol of 8.7 mmol/l,
he presence of tendon xanthomas and angina since the age
f 29 years. When the LDL-receptor gene in this patient was
mplified from genomic DNA and sequenced, the patient was
ound to be heterozygous for two common polymorphisms,
tuI in exon 8 [13] and MspI in exon 15 [14], but the only
ovel variant observed was a heterozygous single base sub-
titution in codon R406 in exon 9 (where 1 is the Met initiator
odon).
Since this base substitution changed codon 406 (R385 in
he mature protein) from CGG to AGG, which is also pre-
icted to encode an Arg residue, it was at first assumed to
e a silent polymorphism. However, since no other potential
efects in LDLR were found in this patient, the possibility
hat this variant was pathogenic was explored, and inspection
f the sequence revealed the presence of a possible cryptic
plice site activated by this single base substitution (Fig. 1).
alculation of the “splice site score” suggested that the new
plice site (score 8.0) was at least as likely to be used as the
atural splice site (score 6.7)
To determine whether the nucleotide variant in exon 9
id affect splicing, a fragment of LDL receptor mRNA was
mplified by RT-PCR from RNA isolated from Epstein-Barr
irus (EBV)-transformed lymphocytes from the patient and
ts nucleotide sequence was determined. As shown in Fig. 2A,
he sequence revealed the presence of a heterozygous deletion
n exon 9 of the mRNA, although the “mutant” mRNA was
nly present at a low level. The extent or nature of the deletion
n the mRNA was not clear, and thus the amplified mutant
ragment was cloned and sequenced. This showed that the
utant mRNA comprised exon 8 spliced to part way along
xon 9, with the first 31 bp of exon 9 deleted from the mature
RNA, and that the mutant allele carried the common G of
he StuI polymorphism (Fig. 2B).
ient. (A) Diagram of part of the LDL receptor gene with exons represented
d in the patient indicated by an arrow above exon 9. The sequence of the
ase substitution in codon 406. The splice scores for the natural splice site
.cshl.edu/new alt exon db2/HTML/score.html), based on the algorithm of
deletion of 31bp from the start of exon 9.
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Fig. 2. Nucleotide sequence of amplified LDL receptor mRNA. (A) Total mRNA was isolated from EBV-transformed lymphocytes from the patient and from
a control subject, and a fragment encompassing exons 7–18 (approximately 1.7 kb) was amplified by RT-PCR and sequenced with a primer in exon 7. The
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[unction between exons 8 and 9 is indicated, together with the region in th
eletion in the mRNA. (B) The amplified fragments were cloned and seque
ubject and the shorter fragment of the patient’s mRNA; the site of the 31 b
To determine whether the splicing defect was partial, i.e.
hether only part of the mutant mRNA was mis-spliced, we
ompared the sequences surrounding two polymorphic sites
n the patient’s genomic DNA and transcribed mRNA. As
an be seen from Fig. 3, this showed that the majority of the
RNA was derived from one allele only; in the case of the
tuI polymorphism in exon 8, this is known to be the “normal”
llele (Fig. 2B), suggesting that little or no full length mRNA
rom the mutant allele is present in the total mRNA (Fig. 3A).
f splicing were only partially defective, the proportion of the
wo bases at the polymorphic sites would be equivalent in total
a
n
p
m
ig. 3. Nucleotide sequences of amplified genomic DNA and mRNA from the pati
13]. (B) Fragment of exon 15, showing the MspI polymorphism [14].t where there appears to be double sequence, indicative of a heterozygous
he sequences shown are from the normal length fragment from the control
n of exon 9 is indicated.
RNA. Similarly, at the MspI polymorphic site, there was a
uch lower than expected amount of the G allele, presumably
resent on the mutant allele of the LDLR (Fig. 3B)
Thus we conclude that the single base substitution in exon
introduces a new splice site that is used to the exclusion of
he normal splice site; this is important because some cryptic
plice sites can be used to only a small extent. The reduced
mount of the aberrantly spliced mRNA is probably due to
onsense-mediated decay [15], because the 31 bp deletion is
redicted to introduce a premature termination codon into the
RNA five codons after G396, the end of exon 8.
ent. A. Sequence of a fragment of exon 8, showing the StuI polymorphism
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rying the recurrent Pro664Leu mutation in a patient with homozygous20 M. Bourbon et al. / Athe
Reviewing previous LDL-receptor gene sequencing data,
e noted that the same heterozygous base substitution was
resent in the genomic DNA of a Chinese homozygous FH
atient in whom we believed we had not detected any defect in
he LDL-receptor gene (subject no. 1 described by Sun et al.
16]). No cells were available to us from this Chinese patient,
nd at that time we had failed to note that the nucleotide
ubstitution might introduce a splice site and had dismissed
t as a rare silent polymorphism. The difference in origins of
he two patients suggests that this mutation is very unlikely
o have been inherited from a common ancestor, and since
t has recurred, it may be in other populations as well [17].
ur findings again emphasize the care that must be taken
efore reporting the presence or absence of a mutation in the
DL-receptor gene for diagnostic purposes.
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